Amylyx Pharmaceuticals
Biopharmaceutical company focused on developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Notes
Amylyx Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was founded by two Brown University students, Justin Klee and Joshua Cohen, who developed AMX0035 (sodium phenylbutyrate/taurursodiol) as a potential ALS treatment.
AMX0035 (branded as Relyvrio in the US, Albrioza in Canada) received FDA approval in September 2022 under accelerated approval. However, in April 2024, Amylyx announced it would voluntarily withdraw Relyvrio from the market after the confirmatory Phase 3 PHOENIX trial did not meet its primary endpoint.
Team
- Justin Klee - Co-founder & Co-CEO
- LinkedIn: linkedin.com/in/justinklee
- Joshua Cohen - Co-founder & Co-CEO
- LinkedIn: linkedin.com/in/joshuacohen
- Margaret Bhola - Chief Financial Officer
- Yuki Sato - Chief Medical Officer
Additional Research Findings
- In Bain Capital Life Sciences portfolio
- Founded by Brown University students Justin Klee and Joshua Cohen
- Publicly traded on Nasdaq (ticker: AMLX)
- AMX0035 (Relyvrio) received FDA accelerated approval in September 2022
- Phase 3 PHOENIX trial did not meet primary endpoint (April 2024)
- Voluntarily withdrawing Relyvrio from US and Canadian markets
- Continuing to explore other neurodegenerative disease applications
- Pipeline includes AMX0114 for Wolfram syndrome